Novo Seeds invests in Dutch biotech firm with NASH focus again

For the third time, Novo Holding's venture arm Novo Seeds has invested in biotech company Northsea Therapeutics. This will allow the latter to start a phase III study of a candidate within NASH and continue phase I and II studies of other candidates.
Søren Møller, Leading Partner at Novo Seeds | Photo: Novo Holdings / PR
Søren Møller, Leading Partner at Novo Seeds | Photo: Novo Holdings / PR
by albert rønning-andersson, translated by catherine brett

Novo Seeds, the department of Novo Holdings which works with early investments, has expressed confidence in Northsea Therapeutics by investing in it for the third time.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading